Get started
Author

Jianyong Chen

ORCID: 0000-0002-3440-0366
Observed ORCID: 0000-0002-3440-0366
OpenAlex ID: A5016097339
Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy
2022 · Jing Deng, Aneel Paulus, et al. · Clinical Cancer Research · 58
Supplementary Tables from Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy
2023 · Jing Deng, Aneel Paulus, et al.
PDF
Supplementary Figures from Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy
2023 · Jing Deng, Aneel Paulus, et al.
PDF
Supplementary Data from Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy
2023 · Jing Deng, Aneel Paulus, et al.
Data from Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy
2023 · Jing Deng, Aneel Paulus, et al.
Data from Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy
2023 · Jing Deng, Aneel Paulus, et al.
Supplementary Figures from Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy
2023 · Jing Deng, Aneel Paulus, et al.
Supplementary Tables from Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy
2023 · Jing Deng, Aneel Paulus, et al.
Supplementary Data from Lisaftoclax (APG-2575) Is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy
2023 · Jing Deng, Aneel Paulus, et al.
Works count: 9
Citation count: 58
H-index: 1
I10-index: 1
Year
Topic
Type